EBVALLO (tabelecleucel)
EBVALLO is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
Ebvallo - European Medicines Agency (EMA)
Oct 14, 2022 · Ebvallo is a medicine used to treat adults and children from 2 years of age who, after receiving an organ- or a bone marrow-transplantation, develop a blood cancer called Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European ...
Dec 19, 2022 · EBV+ PTLD is a rare, acute, and potentially deadly hematologic malignancy that occurs after transplantation when a patient’s T-cell immune response is compromised by immunosuppression. It can impact patients who have undergone solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT).
About EBVALLO: Mechanism of Action, Manufacturing, Treatment …
EBVALLO is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
Ebvallo (tabelecleucel): What is it and is it FDA approved ... - Drugs.com
Jan 17, 2025 · Ebvallo FDA Approval Status. Last updated by Judith Stewart, BPharm on Jan 17, 2025.. FDA Approved: No Brand name: Ebvallo Generic name: tabelecleucel Company: Atara Biotherapeutics, Inc. Treatment for: EBV-Positive Post-Transplant Lymphoproliferative Disease Tabelecleucel (tab-cel) is an allogeneic, EBV-specific T-cell immunotherapy in development …
Ebvallo (tabelecleucel) is an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy which targets and eliminates EBV-positive cells in a human leukocyte antigen (HLA)-restricted manner. Tabelecleucel is produced from T cells harvested from human donors.
Efficacy | EBVALLO
EBVALLO is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy.
What is Ebvallo and what is it used for? Ebvallo is a medicine used to treat adults and children from 2 years of age who, after receiving an organ- or a bone marrow-transplantation, develop a blood cancer called Epstein-Barr virus positive post …
Tabelecleucel: First Approval | Molecular Diagnosis & Therapy
Apr 5, 2023 · Tabelecleucel (Ebvallo TM) is an allogeneic Epstein–Barr virus (EBV)-specific T-cell immunotherapy that targets and eliminates EBV positive (EBV +) cells in a human leukocyte antigen (HLA) restricted manner.
Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European ...
Dec 19, 2022 · EBV+ PTLD is a rare, acute, and potentially deadly hematologic malignancy that occurs after transplantation when a patient's T-cell immune response is compromised by immunosuppression. It can...
- Some results have been removedSome results have been hidden because they may be inaccessible to you.Show inaccessible results